{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "VATC|ANTIFUNGALS FOR DERMATOLOGICAL USE|ANTIFUNGALS FOR TOPICAL USE|Antibiotics" in comments (approximate match)
Showing 1 - 7 of 7 results
Status:
US Approved Rx
(1978)
Source:
NDA050514
(1978)
Source URL:
First approved in 1978
Source:
NDA050514
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Natamycin (Pimaricin, Pimafucin, Natadrops, Natacyn) is a polyene antifungal agent originally isolated from Streptomyces natalensis found in a soil sample from Natal, South Africa. Natamycin was discovered in DSM laboratories in 1955. Similar to other polyenes, natamycin binds to ergosterol in the fungal cell membrane. Natamycin blocks fungal growth by binding specifically to ergosterol with¬out permeabilizing the membrane where it inhibits vacuole fusion at the priming phase and interferes with membrane protein functions. Natamycin is also used in the food industry as an effective preservative. Natamycin is active against most Candida spp. Aspergillus spp., Fusarium spp. and other rarer fungi that cause keratitis. Secondary or acquired resistance is probably rare, but not extensively studied. Natamycin is not effective in vitro against gram-positive or gram-negative bacteria. Topical administration appears to produce effective concentrations of natamycin within the corneal stroma but not in intraocular fluid. Natamycin is poorly soluble in water and not absorbed through the skin or mucous membranes, including the vagina. Very little is absorbed through the gastrointestinal tract. After ocular application, therapeutic concentrations are present within the infected cornea, but not in intra-ocular fluid Natamycin may cause some irritation on skin or mucous membranes
Status:
US Approved Rx
(2007)
Source:
ANDA065394
(2007)
Source URL:
First approved in 1959
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Griseofulvin is a mycotoxic metabolic product of Penicillium spp. It was the first available oral agent for the treatment of dermatophytoses and has now been used for more than forty years. Griseofulvin is fungistatic with in vitro activity against various species of Microsporum Epidermophyton, and Trichophyton. It has no effect on bacteria or on other genera of fungi. Following oral administration, griseofulvin is deposited in the keratin precursor cells and has a greater affinity for diseased tissue. The drug is tightly bound to the new keratin which becomes highly resistant to fungal invasions. Once the keratin-Griseofulvin complex reaches the skin site of action, it binds to fungal microtubules (tubulin) thus altering fungal mitosis. Griseofulvin is fungistatic, however the exact mechanism by which it inhibits the growth of dermatophytes is not clear. It is thought to inhibit fungal cell mitosis and nuclear acid synthesis. It also binds to and interferes with the function of spindle and cytoplasmic microtubules by binding to alpha and beta tubulin. It binds to keratin in human cells, then once it reaches the fungal site of action, it binds to fungal microtubes thus altering the fungal process of mitosis.
Status:
Possibly Marketed Outside US
Source:
Pecilocin by Takeuchi, S. et al.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Variotin (Pecilocin), an antifungal antibiotic, is produced by Paecilomyces varioti Bainer var. antibioticus and was isolated by Takeuchi et al. (1959). It is used topically for the treatment of human dermatomycosis.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Pyrrolnitrin is an antifungal antibiotic and is most active against dermatophytic fungi, especially the species of Trichophyton. Fist, physical and chemical properties of pyrrolnitrin was described by Arima et al. It is synthesized from tryptophan, and the synthesis is probably initiated by a chloroperoxidase enzyme system acting on tryptophan. The present report deals with the mechanism of action of pyrrolnitrin. Pseudomonas pyrrocinia and other Pseudomonas species produce pyrrolnitrin from tryptophan as secondary metabolite. Pyrrolnitrin inhibits fungal growth by inhibiting the respiratory electron transport system.
Status:
US Approved Rx
(2016)
Source:
ANDA208136
(2016)
Source URL:
First approved in 1954
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Class:
MIXTURE